Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Intermediate- and high-risk melanoma.

Sanjiv S Agarwala1

  • 1University of Pittsburgh, N-755 MUH, 200 Lothrop Street, Pittsburgh, PA 15261, USA. agarwalass@msx.upmc.edu

Current Treatment Options in Oncology
|June 12, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Phase 1b Study of Tovorafenib, Plozalizumab or Vedolizumab Plus Standard-of-Care Immune Checkpoint Inhibitors in Patients with Advanced Melanoma.

Journal of Cancer·2025
Same author

Systemic Therapy for Melanoma: ASCO Guideline Update Q and A.

JCO oncology practice·2023
Same author

Systemic Therapy for Melanoma: ASCO Guideline Update.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2023
Same author

Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 1st-3rd, 2022-Naples, Italy).

Journal of translational medicine·2023
Same author

Phase 1 study of the pan-RAF inhibitor tovorafenib in patients with advanced solid tumors followed by dose expansion in patients with metastatic melanoma.

Cancer chemotherapy and pharmacology·2023
Same author

Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 2nd - 4th, 2021, Italy).

Journal of translational medicine·2022
Same journal

Interaction between Regulated Cell Death Pathways and Core Cellular Processes: Unraveling the Molecular Mechanisms of Cardiotoxicity of Antitumor Drugs.

Current treatment options in oncology·2026
Same journal

Advances in Immunotherapy for Breast Cancer: Up-to-date Strategies of Immune Checkpoint Inhibitors and Therapeutic Vaccines.

Current treatment options in oncology·2026
Same journal

Recent Advances in Neoadjuvant Treatment of Anaplastic Thyroid Carcinoma: A Narrative Review.

Current treatment options in oncology·2026
Same journal

The Immunological Landscape of the Tumor Microenvironment: Implications for Immunotherapy of Unresectable and Metastatic Soft Tissue Sarcomas.

Current treatment options in oncology·2026
Same journal

Oncofertility in the Age of HER2 Blockade, Immunotherapy, PARP inhibitors, CDK4/6 inhibitors and Endocrine Treatment: Unanswered Questions in Breast Cancer.

Current treatment options in oncology·2026
Same journal

Emerging Applications of CAR-T Cell Therapy in Overcoming Resistance and Expanding Targets in Hematologic Malignancies: Insights from Recent Research.

Current treatment options in oncology·2026
See all related articles

High-dose interferon alfa-2b (HDI) significantly improved survival for high-risk melanoma patients. Lower doses and other strategies show less promise, necessitating further clinical trial enrollment for effective adjuvant melanoma therapies.

Area of Science:

  • Oncology
  • Melanoma Research
  • Adjuvant Therapy

Background:

  • Melanoma patients with intermediate and high recurrence risk face significant relapse and metastasis threats despite surgical treatment.
  • Effective adjuvant therapies are crucial for improving outcomes in these high-risk melanoma populations.
  • Current research focuses on refining interferon-based treatments and exploring novel therapeutic strategies.

Purpose of the Study:

  • To evaluate the efficacy of adjuvant high-dose interferon alfa-2b (HDI) in high-risk melanoma patients.
  • To assess the effectiveness of different interferon dosages and biochemotherapy regimens.
  • To identify optimal adjuvant therapies for intermediate-risk melanoma patients.

Main Methods:

  • Analysis of randomized trials involving adjuvant therapy with high-dose interferon alfa-2b (HDI) in high-risk melanoma patients.

Related Experiment Videos

  • Comparison of HDI with interleukin-2 based biochemotherapy for a subset of highest-risk patients in an ongoing phase III trial.
  • Evaluation of intermediate-dose interferon and other novel approaches like vaccines.

    • Main Results:

    • Adjuvant HDI significantly improved relapse-free and overall survival rates in high-risk melanoma patients.
    • Lower-dose interferon regimens have not shown convincing success, despite reduced toxicity.
    • No effective adjuvant therapy is currently available for intermediate-risk melanoma.

    Conclusions:

    • High-dose interferon alfa-2b (HDI) is an effective adjuvant therapy for high-risk melanoma.
    • Further research and clinical trials are needed to establish effective treatments for intermediate-risk melanoma.
    • Enrollment in clinical trials for shorter HDI courses or vaccines is recommended for intermediate-risk patients.